FGF21 and metabolic dysfunction-associated steatohepatitis: Although we did not assess bile acid levels in the present study, pegbelfermin has been reported to reduce circulating secondary bile acid levels in patients with MASH [46], supporting that FGF21 analogs can improve bile acid homeostasis in MASH.